Clinical Trials Arena on MSN11d
Blue Earth’s radioligand therapy achieves high tumour radiation absorptionResults from the company’s Phase I/II trial showed the injectable therapy to have an effective half-life of 91.4 hours.
Imaging company Bracco is to buy Blue Earth Diagnostics for $450 million, netting £337 million for its owner Syncona, the UK’s largest listed life sciences investment firm.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback